Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
Apply
Pirtobrutinib, Venetoclax, Obinutuzumab
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step